The latest price target for Takeda Pharmaceutical Co (NYSE:TAK) was reported by TD Cowen on May 16, 2023. The analyst firm set a price target for $20.00 expecting TAK to rise to within 12 months (a possible 51.98% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Takeda Pharmaceutical Co (NYSE:TAK) was provided by TD Cowen, and Takeda Pharmaceutical Co maintained their outperform rating.

The last upgrade for Takeda Pharmaceutical Co Ltd happened on March 16, 2023 when B of A Securities raised their price target to $20. B of A Securities previously had a neutral for Takeda Pharmaceutical Co Ltd.

There is no last downgrade for Takeda Pharmaceutical Co.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Takeda Pharmaceutical Co, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Takeda Pharmaceutical Co was filed on May 16, 2023 so you should expect the next rating to be made available sometime around May 16, 2024.

While ratings are subjective and will change, the latest Takeda Pharmaceutical Co (TAK) rating was a maintained with a price target of $30.00 to $20.00. The current price Takeda Pharmaceutical Co (TAK) is trading at is $13.16, which is out of the analyst’s predicted range.